Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | PDE9A | O76083 | 3/20 | 0.43 |
| ▸ | PDE1A | P54750 | 3/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6366948 | 0.88 | PDE9A (0.46) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366064 | 0.88 | GRIN1 (0.47) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6367368 | 0.87 | PNP (0.50) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6368253 | 0.87 | PDE9A (0.52) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6370895 | 0.87 | PLA2G2A (0.46) | SMN1; SMN2PDE9APDE1APDE1BPDE1C | |
| SCHEMBL6367562 | 0.86 | PDE9A (0.52) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366736 | 0.86 | PDE9A (0.44) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366055 | 0.85 | PDE9A (0.51) | ADORA3PDE9APDE1APDE1BPDE1C | |
| SCHEMBL6367309 | 0.85 | PDE9A (0.53) | SMN1; SMN2ADORA3PDE9APDE1APDE1B | |
| SCHEMBL6366904 | 0.84 | PDE9A (0.50) | PDE9APDE1APDE1BPDE1CPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | SMN1; SMN2 2040/4885ADORA3 1281/4885PDE9A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.